A detailed history of Core Cap Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Core Cap Advisors, LLC holds 243 shares of CRSP stock, worth $12,050. This represents 0.0% of its overall portfolio holdings.

Number of Shares
243
Holding current value
$12,050
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$51.17 - $68.18 $12,434 - $16,567
243 New
243 $13,000
Q4 2022

Feb 10, 2023

BUY
$39.19 - $65.67 $2,077 - $3,480
53 New
53 $2,000
Q2 2022

Aug 11, 2022

BUY
$43.23 - $73.83 $4,106 - $7,013
95 New
95 $6,000
Q1 2022

Apr 29, 2022

SELL
$53.19 - $79.24 $2,233 - $3,328
-42 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$70.09 - $111.29 $2,943 - $4,674
42 New
42 $3,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.87B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.